Glenmark received a USFDA warning for its Indore plant, but expects no supply or revenue disruptions from the notice.

• FDA inspection occurred in February 2025; no data integrity issues were flagged during the audit.
• Glenmark commits to resolving concerns quickly and maintaining strict CGMP standards across all manufacturing facilities.
• The company focuses on respiratory, dermatology, and oncology therapies across branded, generics, and OTC product segments globally.